Longevity.Technology UNLOCKED

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

__________________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GeneRare funding, Noom's pharmacy buy, Anovis neuro combos, Life Biosciences reprogramming, wearable partnerships, and Peloton at Longevity Show.

• Generare raised $21.6M (€20M) Series A to scale microbial genome scanning for novel natural product molecules, identifying 200+ hits in 2025. Funds expand libraries from plants, fungi, marine sources and team to 50 for bioactive drug leads. AI optimizes hits despite supply/IP challenges, eyeing geroprotectors like rapamycin analogs.
• Noom acquired a 503A compounding pharmacy to dispense GLP-1s, peptides like sermorelin, NAD+ with behavioral coaching for healthy aging. Vertical integration pairs app data with pharma access to scale longevity interventions. Success needs strong clinical governance over revenue incentives.
• Annovis advances buntanetap, oral molecule from Calabar bean "execution poison," reducing amyloid beta, tau, alpha-synuclein translation in phase 3 Alzheimer's and Parkinson's trials. Combos with sildenafil boost cerebral blood flow, NO-cGMP as vascular support.
• Life Biosciences landed $80M Series D to push ER-100 partial epigenetic "cell reset" therapy into phase 1 for optic neuropathies like glaucoma. Targets retinal ganglion cell rejuvenation as beachhead for organ-specific proofs toward systemic aging reversal. Measurable vision outcomes validate reprogramming.
• Agentis partners Ultrahuman integrating CGM/HRV into Longevity Quotient platforms; Well Health ties AliveCor for AI-ECG AFib detection in Canada. Wearables enable dynamic monitoring beyond snapshots for arrhythmias, metabolic drift. Demand proven clinical outcomes over data noise.
• Peloton named official movement partner for Longevity Show 2026 (June 26-27, London) with rooftop workouts, 5K runs, rave featuring Leanne Hainesby. Anchors exercise as healthspan core alongside biomarkers, bridging fitness-longevity audiences. Preview April 19 Covent Garden.

______________________

News & References:

• Generare bags $21.6m for nature-derived drug leads → https://longevity.technology/news/generare-bags-21-6m-for-nature-derived-drug-leads/
• Noom buys pharmacy to push into healthy aging → https://longevity.technology/news/noom-buys-pharmacy-to-push-into-healthy-aging/
• Annovis traces buntanetap’s road to Alzheimer’s → https://longevity.technology/news/annovis-traces-buntanetaps-road-to-alzheimers/
• Life Biosciences lands $80m to push cell reset therapy → https://longevity.technology/news/life-biosciences-lands-80m-to-push-cell-reset-therapy/
• Agentis, Ultrahuman tie wearables to longevity care → https://longevity.technology/news/agentis-ultrahuman-tie-wearables-to-longevity-care/
• Peloton named Movement Partner for The Longevity Show 2026 → https://longevity.technology/news/peloton-named-movement-partner-for-the-longevity-show-2026/

______________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

______________________

Guests:

Ashley Zehnder

CEO, Fauna Bio

Linkedin: www.linkedin.com/in/ashley-zehnder-31950827/

Website: faunabio.com/

Daniel Oliver

Co-Founder & CEO, Rejuvenate Bio

Linkedin: www.linkedin.com/in/danielcoliver/

Website: rejuvenatebio.com/

______________________

What if the animal kingdom holds the key to improving human healthspan and performance?

Phil Newman and Dr. Nina Patrick sit down with Ashley Zehnder, CEO of Fauna Bio, and Daniel Oliver, CEO of Rejuvenate Bio, to explore how insights from hibernating animals, long-lived species, and regenerative models are shaping next-generation longevity therapies. From metabolic adaptations and ketone utilization to epigenetic reprogramming, they reveal how studying other species can guide interventions for human health, recovery, and overall wellness.

Together they explain how species that naturally resist disease, survive extreme conditions, or regenerate tissues provide a roadmap for interventions in humans. From hibernating mammals that switch to ketone-based metabolism to long-lived rodents showing epigenetic resilience, these insights are shaping therapies that target recovery, metabolism, and overall wellness.

They also discuss how these discoveries could inform practical strategies for human health, from personalized nutrition and exercise to novel drug targets that mimic nature’s resilience.

In this episode, you’ll learn:

• How gene therapies in animals improve endurance, recovery, frailty, and lifespan- What hibernating animals and high-performance species teach about metabolism and resilience
• How AI and comparative genomics accelerate drug discovery and improve translational success
• Common misconceptions about translating animal biology to human health
• Future priorities in longevity research, including regenerative biology and disease resistance

If you want to understand how comparative biology and cutting-edge therapies are unlocking new pathways to enhance human healthspan, this episode connects science from the animal kingdom with actionable insights for human longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.

• PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.
• Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.
• Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.
• Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor.
• Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.
• Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.

______________________

News & References:

• PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/
• Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/
• Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/
• Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/
• Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/
• Private clinics face longevity learning curve → https://longevity.technology/news/private-clinics-face-longevity-learning-curve/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: ⁠fatty15.com/UNLOCKED

______________________

Guests: Dr. Aubrey de Grey

President and CSO at LEV Foundation

Linkedin: www.linkedin.com/in/aubrey-de-grey-24260b/

Website: www.levf.org/

______________________

What if aging is not inevitable… but something we can actively manage?

Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.

Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.

Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.

In this episode, you’ll learn:

• How intrinsic capacity and resilience can measure functional aging earlier than traditional methods
• Why preventative medicines face societal and regulatory barriers
• How high-profile advocates and clinics are shaping public acceptance of longevity therapies
• Ethical and practical considerations for equitable access worldwide
• Where Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040

If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Affiliate link: https://www.getstride.com/unlocked/

____________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore cutting-edge developments in longevity, from hibernating animals inspiring obesity treatments to AI-driven industry insights and the world’s first Parkinson’s test kit.

• FaunaBio identified a metabolic target from hibernating mammals that could preserve muscle during weight loss. The California-based company said the achievement triggers an undisclosed milestone payment as part of a multi-year agreement signed with Lilly in 2023, which could be worth up to $494 million. This will advance this first-in-class approach, signaling serious pharma conviction in extreme-animal-inspired drug discovery.
• Longevity.Technology developed DLT (Decoding Longevity Trends), a three-stage AI system to gather, fact-check, and synthesize complex longevity data. DLT tracks over 700 longevity and age-related disease biotechs in paid-beta; the broader datasets (800+ wider ecosystem companies and 300+ longevity clinics) will be released in 2H26.
• The MODAG's PD Detect kit measures alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, moving Parkinson’s diagnosis from observation to evidence. Early detection can help enroll patients at stages where disease-modifying drugs have the best chance of success.
• The Senotherapeutics Biomarker Consortium (SBC) aims to standardize cellular senescence measurement in humans to support regulators, clinicians, and drug development. Framed as a precompetitive collaboration, it brings together academia, industry and regulators to do something less glamorous than drug discovery, but arguably more necessary – to agree on how senescence should be measured, validated and ultimately trusted in the clinic.
• The experimental pill Enlicitide lowered LDL cholesterol by 57% in a phase three trial of 2,909 patients with cardiovascular risk. Daily oral dosing could finally improve compliance compared with injectable PCSK9 inhibitors, potentially reducing cardiovascular events at a population level.
• Cardiovascular disease and cancer (particularly colon cancer) and “external causes” remain top mortality risks. These conditions are leading causes of death for Gen X and Millennials, highlighting the urgent need for early detection and preventive health strategies.

____________________

News & References:

• Fauna Bio hits key milestone in Lilly obesity drug collab → https://longevity.technology/news/fauna-bio-hits-key-milestone-in-lilly-obesity-drug-collab/
• Longevity.Technology has quietly become an AI company → https://longevity.technology/news/longevity-technology-has-quietly-become-an-ai-company/
• MODAG brings world’s first Parkinson’s test to market → https://longevity.technology/news/modag-brings-worlds-first-parkinsons-test-to-market/
• Senescence consortium targets biomarker gap → https://longevity.technology/news/senescence-consortium-targets-biomarker-gap/
• Experimental pill cuts ‘bad cholesterol’ by up to 60% → https://longevity.technology/news/experimental-pill-cuts-bad-cholesterol-by-up-to-60/
• Longevity wake-up call for younger generations → https://longevity.technology/news/longevity-wake-up-call-for-younger-generations/

____________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:

Dr Lara Briden

Naturopathic doctor and Bestselling Author

Instagram: www.instagram.com/larabriden/

Website: www.larabriden.com/

Dr Molly Maloof

Educator, Author, and Founder of Adamo

Instagram: www.instagram.com/drmolly.co/?hl=en

Website: https://drmolly.co/

______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: www.getstride.com/unlocked/

______________________

What if the key to female longevity has been hiding in plain sight?

In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.

They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.

Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.

In this episode, you’ll learn:

• Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.
• How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.
• The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.
• The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.
• How evolutionary biology explains menopause as a “superpower” for human survival.
• Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.
• The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.

If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.

• Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.
• Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.
• South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals.
• Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.
• The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.
• Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.

______________________

News & References:

• Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/
• Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/
• Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/
• Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/
• ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/
• Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:

Dr. Dave Rabin MD, PhD

Founder of Apollo Neuro

Linkedin: www.linkedin.com/in/drdavemdphd/

Website: https://apolloneuro.com/

Dr Pedram Shojai

Founder of The Urban Monk

Instagram:www.instagram.com/drpedramshojai/

Website: https://theurbanmonk.com/

___________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: www.getstride.com/unlocked/

___________________

What if stress isn’t something to eliminate… but something to train?

Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.

Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.

Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.

Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.

In this episode, you’ll learn:

• How chronic stress alters brain function, sleep, and long-term health
• Why recovery should be scheduled like performance
• How breathwork and somatic practices activate safety pathways
• The role of circadian rhythm in resilience and cognition
• Where wearable technology helps and where it doesn’t

If you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.

___________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic longevity platforms.

• A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.
• New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.
• In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.
• Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.
• In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.
• Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies.

_____________________

News & References:

• GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/
• Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/
• Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/
• Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/
• Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/
• Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/

_____________________

Hosts:

Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠

Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠

Guests:

Dr James Goolnik

Founder of Optimal Dental Health

Instagram: www.instagram.com/jamesgoolnik/?hl=en

Website: www.optimaldentalhealth.co.uk/

Dr Aoife Stack

Co-founder of Airway School

Instagram: www.instagram.com/doctor_aoife/?hl=en

Website: www.airwayschool.co.uk

______________________

What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.

Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.

The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.

This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.

In this episode, you’ll learn:

• Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain health
• How simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and posture
• The role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilience
• Strategies for sustainable sugar reduction and habit stacking to protect oral and systemic health

If you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.

Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠